Table 3.

Multivariable-adjusted associations for combined PCPT treatment arms of serum 25(OH)D concentrations and prostate cancer risk in the PCPT by age and BMI

All cancerGleason 2–6Gleason 7Gleason 8–10
Case/controlORa (95% CI)Case/controlORa (95% CI)Case/controlORa (95% CI)Case/controlORa (95% CI)
Age, y
<65
 Q1b213/260Ref139/260Ref47/260Ref20/260Ref
 Q2b243/2471.02 (0.78–1.33)174/2471.11 (0.82–1.48)44/2470.86 (0.55–1.36)18/2470.87 (0.44–1.71)
 Q3b256/2531.01 (0.77–1.32)188/2531.12 (0.83–1.50)43/2530.80 (0.50–1.27)14/2530.65 (0.31–1.36)
 Q4b288/2311.16 (0.89–1.52)207/2311.26 (0.94–1.68)58/2311.11 (0.72–1.73)15/2310.73 (0.35–1.51)
0.280.150.650.30
65+
 Q1b145/161Ref86/161Ref32/161Ref20/161Ref
 Q2b151/1730.89 (0.64–1.22)92/1730.87 (0.60–1.27)36/1731.02 (0.60–1.74)12/1730.56 (0.27–1.20)
 Q3b193/1661.15 (0.84–1.57)116/1661.12 (0.78–1.61)48/1661.35 (0.82–2.25)18/1660.85 (0.43–1.69)
 Q4b206/1911.03 (0.76–1.41)139/1911.14 (0.80–1.62)46/1911.09 (0.66–1.81)10/1910.40 (0.18–0.88)
0.470.220.550.07
Pinteraction0.800.990.990.52
BMIc
<25
 Q1b66/94Ref47/94Ref10/94Ref7/94Ref
 Q2b95/811.33 (0.84–2.09)71/811.34 (0.81–2.20)18/811.88 (0.81–4.37)4/810.59 (0.16–2.15)
 Q3b145/1101.49 (0.97–2.27)101/1101.39 (0.87–2.23)26/1101.96 (0.88–4.37)8/1100.81 (0.27–2.39)
 Q4b176/1491.26 (0.84–1.90)122/1491.18 (0.76–1.86)40/1492.13 (0.99–4.59)8/1490.54 (0.18–1.59)
0.790.660.080.34
25–<30
 Q1b172/200Ref104/200Ref43/200Ref17/200Ref
 Q2b212/2250.99 (0.75–1.32)140/2251.07 (0.77–1.48)41/2250.78 (0.48–1.25)19/2251.00 (0.50–2.01)
 Q3b220/2300.95 (0.72–1.27)149/2301.06 (0.77–1.47)45/2300.78 (0.49–1.25)17/2300.85 (0.41–1.74)
 Q4b258/2251.11 (0.84–1.48)188/2251.33 (0.97–1.82)48/2250.83 (0.52–1.33)12/2250.60 (0.23–1.31)
0.470.080.510.18
30+
 Q1b120/127Ref74/127Ref26/127Ref16/127Ref
 Q2b87/1140.71 (0.48–1.05)55/1140.71 (0.45–1.11)21/1140.83 (0.44–1.58)7/1140.46 (0.18–1.17)
 Q3b84/791.00 (0.66–1.51)54/791.00 (0.63–1.60)20/791.16 (0.60–2.27)7/790.66 (0.25–1.73)
 Q4b60/481.02 (0.64–1.64)36/480.97 (0.57–1.66)16/481.32 (0.63–2.73)5/480.69 (0.23–2.05)
0.760.890.370.44
Pinteractiond0.470.410.280.61

NOTE: Vitamin D standardized for month of blood draw before dividing into quartiles based on distribution in controls.

  • aORs adjusted for age (except age-stratified models), race (White, African American, other race), and treatment (finasteride, placebo).

  • bQuartile cutoff points based on the distribution in controls in each strata.

  • cThirty-three men missing BMI data were not included in BMI stratified analyses.

  • dInteraction tested as the cross-product of 25(OH)D concentration rank (lowest to highest quartile) and an indicator for age (<65, ≥65) or BMI (<25, 25–<30, ≥30).